Is Ampliphi Biosciences Corporation (NYSEAMERICAN:APHB) a Buy? The Stock Reported more Sellers

October 2, 2018 - By Hugh Holland

AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) Logo

The stock of Ampliphi Biosciences Corporation (NYSEAMERICAN:APHB) registered an increase of 29.29% in short interest. APHB’s total short interest was 1.06 million shares in October as published by FINRA. Its up 29.29% from 821,200 shares, reported previously. With 151,100 shares average volume, it will take short sellers 7 days to cover their APHB’s short positions.

The stock increased 3.06% or $0.03 during the last trading session, reaching $1.01. About 9,778 shares traded. AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) has 0.00% since October 2, 2017 and is . It has underperformed by 15.62% the S&P500.

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage technology. The company has market cap of $16.63 million. It is also developing targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. It currently has negative earnings. The firm has reported results from two Phase I clinical trials of AB-SA01 for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients, as well as evaluating the safety of AB-SA01 when administered topically to the intact skin of healthy adults.

AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>